Coverage expansion: risks and opportunities. The findings of the ARV drugs procurement monitoring in 2017
ITPCru has published their new report about the results of ARV drugs procurement monitoring in 2017.
The Association of Clinical Trials Organizations published their newsletter “Russian clinical trials market in 2012-2017”. A part about HCV, HIV and TB drugs is included.
We would like to present you our new poster in support of people with HIV who were recently diagnosed. It is called “Good news for people with HIV”. The poster contains separate blocks of information about differents aspects, for example, about a fact that effective treatment exists, people don’t die of HIV anymore, a lifespan is not limited by HIV, HIV
Assessment of HIV treatment adherence among people who use injectable drugs was performed in Kyrgyzstan. It is the first study in the country for all period of ART programmes implementation in the Kyrgyz Republic.
Exit from the labyrinth: the end of decentralization. The results of monitoring of purchases of ARV drugs in Russia in 2016
We are glad to present you the brief english version of the report “Exit from the labyrinth: the end of decentralization. The results of monitoring of purchases of ARV drugs in Russia in 2016”. The purpose of the report is to obtain conclusions based on the analysis of 4500 public procurement monitoring data for ARV drugs in 2016, and to
November 02-04 Tbilisi hosted a meeting dedicated to the issues of access to medicines in terms of the barriers associated with intellectual property. The meeting was attended by representatives from the following pharmaceutical companies: Pharmasyntez (Russia), Biocad (Russia), Cipla (India), Mylan (U.S.), Tatchempharm (Russia), and PharmEvo (Pakistan). The following issues have been discussed at the meeting:
The ITPCru team and SEVT Ltd. have developed a chart “Hepatitis C treatment: recommendations 2016” which includes the recent recommendations for interferon-free treatment of HCV-monoinfected (EASL 2016) and HCV/HIV coinfected patients (EACS 2016). The chart also contains updated tables with all approved direct-acting antiviral drugs, as well as information about drug-drug interactions (HCV/HIV drugs).
ITPCru has updated the ARV drug chart. The chart contains of the new ARVs approved by FDA and EMA, has updated information about daily dosage and treatment regimen, as well as treatment recommendations according to WHO 2016 guidelines.
В таблице “Минимальные, максимальные и средневзвешенные цены на АРВ-препараты в РФ” отражены цены на все препараты для лечения ВИЧ-инфекции, закупленные в 2014 году, включая стоимость единицы (таблетки, капсулы, флакона), а также годового курса лечения одного пациента.